GAIN THERAPEUTICS, INC Foreign Currency Transaction Gain (Loss), before Tax
GAIN THERAPEUTICS, INC (GANX) reported Foreign Currency Transaction Gain (Loss), before Tax of $49.09 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-11
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was $49.09K.
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$165.17K.
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$84.78K, a 638.02% decline year-over-year.
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was -$27.38K.
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), before tax for fiscal 2025 was -$833.67K, a 799.86% decline from fiscal 2024.
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), before tax for fiscal 2024 was $119.12K.
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), before tax for fiscal 2023 was -$429.35K.
- GAIN THERAPEUTICS, INC foreign currency transaction gain (loss), before tax for fiscal 2022 was -$96.07K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $49.09K 10-Q · filed 2026-08-11 | -$116.08K 10-Q · filed 2026-08-11 | -$200.87K derived: sum of 3 quarters · filed 2026-08-11 | -$228.25K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$165.17K 10-Q · filed 2026-05-11 | -$249.95K derived: sum of 2 quarters · filed 2026-05-11 | -$277.34K derived: sum of 3 quarters · filed 2026-05-11 | -$898.26K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$84.78K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$112.16K derived: sum of 2 quarters · filed 2026-03-26 | -$733.09K derived: sum of 3 quarters · filed 2026-08-11 | -$833.67K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$27.38K 10-Q · filed 2025-11-12 | -$648.31K derived: sum of 2 quarters · filed 2026-08-11 | -$748.89K 10-Q · filed 2025-11-12 | -$733.13K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$620.92K 10-Q · filed 2026-08-11 | -$721.51K 10-Q · filed 2026-08-11 | -$705.75K derived: sum of 3 quarters · filed 2026-08-11 | -$826.89K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$100.59K 10-Q · filed 2026-05-11 | -$84.83K derived: sum of 2 quarters · filed 2026-05-11 | -$205.97K derived: sum of 3 quarters · filed 2026-05-11 | -$249.54K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $15.76K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$105.38K derived: sum of 2 quarters · filed 2026-03-26 | -$148.96K derived: sum of 3 quarters · filed 2026-03-26 | $119.12K 10-K · filed 2026-03-26 |
| 2024-09-30 | -$121.14K 10-Q · filed 2025-11-12 | -$164.72K derived: sum of 2 quarters · filed 2025-11-12 | $103.36K 10-Q · filed 2025-11-12 | -$305.14K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$43.58K 10-Q · filed 2025-08-12 | $224.50K 10-Q · filed 2025-08-12 | -$184.01K derived: sum of 3 quarters · filed 2025-08-12 | -$101.81K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $268.08K 10-Q · filed 2025-05-14 | -$140.43K derived: sum of 2 quarters · filed 2025-05-14 | -$58.23K derived: sum of 3 quarters · filed 2025-05-14 | -$118.43K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$408.51K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$326.31K derived: sum of 2 quarters · filed 2025-03-27 | -$386.50K derived: sum of 3 quarters · filed 2025-03-27 | -$429.35K 10-K · filed 2025-03-27 |
| 2023-09-30 | $82.20K 10-Q · filed 2024-11-14 | $22.00K derived: sum of 2 quarters · filed 2024-11-14 | -$20.84K 10-Q · filed 2024-11-14 | -$219.78K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$60.20K 10-Q · filed 2024-08-08 | -$103.04K 10-Q · filed 2024-08-08 | -$301.98K derived: sum of 3 quarters · filed 2024-08-08 | -$258.49K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$42.84K 10-Q · filed 2024-05-14 | -$241.78K derived: sum of 2 quarters · filed 2024-05-14 | -$198.29K derived: sum of 3 quarters · filed 2024-05-14 | -$158.08K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$198.94K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$155.45K derived: sum of 2 quarters · filed 2024-03-26 | -$115.24K derived: sum of 3 quarters · filed 2024-03-26 | -$96.07K 10-K · filed 2024-03-26 |
| 2022-09-30 | $43.49K 10-Q · filed 2023-11-14 | $83.70K derived: sum of 2 quarters · filed 2023-11-14 | $102.86K 10-Q · filed 2023-11-14 | $83.19K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $40.21K 10-Q · filed 2023-08-10 | $59.37K 10-Q · filed 2023-08-10 | $39.70K derived: sum of 3 quarters · filed 2023-08-10 | $12.29K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $19.16K 10-Q · filed 2023-05-12 | -$513.00 derived: sum of 2 quarters · filed 2023-05-12 | -$27.93K derived: sum of 3 quarters · filed 2023-05-12 | -$72.30K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$19.68K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$47.09K derived: sum of 2 quarters · filed 2023-03-23 | -$91.46K derived: sum of 3 quarters · filed 2023-03-23 | -$72.92K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$27.41K 10-Q · filed 2022-11-10 | -$71.78K derived: sum of 2 quarters · filed 2022-11-10 | -$53.24K 10-Q · filed 2022-11-10 | -$101.55K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$44.37K 10-Q · filed 2022-08-08 | -$25.83K 10-Q · filed 2022-08-08 | -$74.14K derived: sum of 3 quarters · filed 2022-08-08 | -$48.55K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $18.54K 10-Q · filed 2022-05-16 | -$29.77K derived: sum of 2 quarters · filed 2022-05-16 | -$4.17K derived: sum of 3 quarters · filed 2022-05-16 | -$9.03K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$48.31K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | -$22.71K derived: sum of 2 quarters · filed 2022-03-25 | -$27.57K derived: sum of 3 quarters · filed 2022-03-25 | -$96.48K 10-K · filed 2022-03-25 |
| 2020-09-30 | $25.60K 10-Q · filed 2021-11-12 | $20.74K derived: sum of 2 quarters · filed 2021-11-12 | -$48.17K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$4.86K 10-Q · filed 2021-08-12 | -$73.77K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$68.91K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |